Free vedolizumab refers to the unbound fraction of vedolizumab circulating in the bloodstream, not complexed with its target, the α4β7 integrin. Vedolizumab is a monoclonal antibody that specifically inhibits lymphocyte adhesion and trafficking to gastrointestinal tissue by blocking interaction with mucosal addressin cell adhesion molecule-1 (MAdCAM-1). Measurement of free vedolizumab levels provides insight into drug bioavailability and target engagement, particularly in patients with inflammatory bowel disease (IBD), where it is used to reduce gut-specific inflammation.
In research and clinical settings, quantifying free vedolizumab is critical for optimizing therapeutic drug monitoring (TDM). TDM helps ensure that drug levels remain within an effective range, allowing clinicians to tailor dosages, avoid under- or overdosing, and assess immunogenicity risk through the detection of anti-vedolizumab antibodies. This is especially relevant for biologics, where immune responses can reduce drug efficacy or alter pharmacokinetics.
Additionally, monitoring free vedolizumab is essential in the development and evaluation of biosimilars, as small variations in manufacturing may impact drug exposure and patient outcomes. Accurate measurement of free drug levels supports robust safety and efficacy assessments during both clinical trials and routine patient management.
This product is manufactured in Turkey by Matriks Biotek.